Boston Scientific released Q3 earnings on 10/18 and subsequently traded down 7% over the next two days compared to market losses of 2%. The company reported adjusted EPS of $0.16 per share, which was in-line with analyst consensus estimates and towards the upper range of management's guidance. Despite this, the stock fell heavily due to continued weakness in the firm's revenues, which fell 5% on a constant currency basis.
BSX reported revenues of $1.74bn compared to $1.87bn over the same period a year ago. The firm has faced significant headwinds in its two main divisions, the Cardiac Rhythm Management and International Cardiology units, which account for 55% of BSX's total revenues. The Interventional Cardiology unit, which produces coronary stents, reported a 20% decline in sales driven by eroding market share from Medtronic's Resolute stent system. Goldman Sachs' analyst, David Roman, estimates the firm lost 5.2% market share YOY in the drug-eluting stent (DES) market primarily due to the Resolute Integrity. Management now estimates the company has mid- to high-30s in DES market share. Going forward, management expects to recapture market share due to the Promus Element, however, we expect the DES market to remain highly competitive with Abbott Laboratories, Medtronic, and Boston Scientific continuing to one-up each other.
BSX also has faced difficulties in the Cardiac Rhythym Management (CRM) unit. Revenues in the CRM unit declined 8% driven by weaknesses in the broader CRM market. The use of implantable cardioverter defibrillators (ICDs) has declined since a research paper in the Journal of the American Medical Association suggested that 23% of ICD implantation were not evidence based, and the procedure should not have taken place. The research paper sparked a Department of Justice investigation into ICD implants, which has made physicians reluctant to perform the procedure without overwhelming evidence. Despite this, current research by UCLA Medical Center found that there are over 850,000 heart failure patients in the US who are eligible for an ICD but have not received one, countering the claim of overuse and suggesting potential growth in the area. Out of the firm's two main segments, CRM is the one with the highest potential for growth. Despite a weakening market, BSX has managed to increase market share with its Ingenio platform. Additionally, BSX has the first subcutaneous S-ICD, which has received early FDA approval, through the acquisition of Cameron Health. The S-ICD has the potential to be a blockbuster product for BSX, as it is the first device of its kind that doesn't require the attachment of electrical wires to the heart, and eliminates serious risks associated with previous devices. Lastly, a recent research paper has suggest the CRM has the potential to become a $12.5bn market by 2017 due to international growth (BSX's CRM sales are currently $462mm), and BSX plants to spend $150mm over the next 5 years to expand into the untapped Chinese market.
Aside from the two main units, BSX saw above-market growth in 7 of 12 business units. Endoscopy and Peripheral Interventions both grew 7% on a constant currency basis, and are the firm's third and fourth largest units. These two units now account for 29% of the firm's revenues, and continue to post mid to high-single digit growth YOY. As these segments continue to growth, less emphasis will be placed on growth in the CRM and IC units.
Despite disappointing sales, BSX has made tremendous strides in profitability. Gross margins expanded 400 bps, from 64% to 68%, as the product mix has shifted from the Promus stent to the Promus Element stent system, which carries significantly higher margins. This trend, however, is not expected to continue into the near future as the shift to the Element is nearly complete.
Overall, Boston Scientific has continued to meet expectations on bottom-line growth and generate strong operating cash flows. Despite this, the stock has continued to trade off top-line growth, particularly within the CRM and IC units. Given the strides in profitability, any signs of strength in the franchise segments will warrant significantly higher valuation for the company. Given the prospects of the S-ICD, international growth in the CRM unit, and continued growth in the PI and Endoscopy units, we believe BSX may finally be on track for positive revenue growth. Management believes the stock is undervalued and is committed to using 50% of cash for share buybacks, which should create shareholder value going forward. BSX currently trades at a discount to peers in P/E, P/S, P/BV, EV/FCF, EV/EBITDA, and PEG, and we do not believe this is an opportune time to exit the stock. In conclusion, we reiterate a BUY rating for Boston Scientific Corporation.
Saturday, October 20, 2012
Verizon Q3 Earnings
Verizon posted strong Q3 results on Thursday, with increasing smartphone adoption. During the third quarter Verizon released their new family data share plans, making it cheaper for customers to add multiple smartphones as well as other internet connected devices, such as tablets and broadband cards. This new plan was met with great success as Verizon was able to add 1.5 million postpaid connections on expectations of only 900,000. Verizon also grew operating income by 18%, in part due to an increase in wireless margins due to slightly lower iPhone sales. IPhone sales were lower in the quarter due to the release of the iPhone 5 very late in the quarter; sales of iPhones were low in anticipation of the new one coming out. Although there were only a couple weeks left when the iPhone 5 released, sales were still strong even though supply was tight, also sales of the iPhone 4 and 4S were strong after the price drop. With stronger sales coming from the android smartphone market as well, smartphones accounted for 53% of all postpaid subscribers, up from 50% last quarter. This bodes well for Verizon because as they increase the amount of smartphones they sell, they are able to charge more for the monthly fees associated with smartphones. Verizon also benefited from charging a $36 activation fee on all upgrades, which was instituted shortly before the third quarter. Verizon also continued to grow their 4G LTE data network and remains the market leader, servicing over 400 markets, almost 5 times as many as competitor AT&T. Verizon had EPS of 64 cents which fell in line with consensus, but earnings had a great market reception due to the increased smartphone adoption which offers promising growth. Verizon continues to outperform competitors and retain market share as the number one wireless carrier in the United States, this puts them in prime position to continue to benefit from the smartphone revolution, as well as the tablet revolution.
Ryan Ranado
CSX Earnings
CSX Corporation released earnings for Q3 2012 on October 16th. They reported a net income of $455 million vs $464 million in Q3 2011, showing a decline of 1.9% year-over-year. This breaks a four-quarter streak of profit increases. A mild winter caused coal demand to be suppressed; coal composes more than a fourth of the revenue for CSX. International volume of the company grew 10%, in part due to the success of the Maersk business. The reported EPS was $.44, beating consensus marginally, which was $.43, and outperforming Q3 2011 earnings of $.43. Reported revenues were $2.89 billion, missing expectations set at $2.93 billion. Shares of CSX were down 2.2% in the afternoon sharing at $21.15.
Looking forward, the company sees itself as a neutral outlook for the fourth quarter. Estimated EPS for Q4 is $.47, and estimates are $1.85 for the fiscal year. Coal will continue to be challenged by low gas prices and high utility stockpiles, but the industrial, agricultural, construction, and domestic sectors all have favorable outlooks. There is uncertainty going forward with the company for Q4, as coal is becoming less demanded and CSX could be looking at moderate labor inflation. CSX sees itself with only moderate growth for the future.
- Peter Rodrigues, Industrial Junior Analyst
Alexion Pharmaceutical dips 5.32%
At Fridays close Alexion Pharmaceuticals (ticker: ALXN) ended the day 5.32% on approximately double its average trading volume. Although the reason for this fall isn't due to a company-specific event, we can attribute this to what has been a weak earnings season. With ALXN due to report Q3 earnings on October 24th, investors may be speculating a ALXN miss. In addition, despite not having any direct competitors, Cubist Pharmaceuticals (ticker: CBST), another niche market biotech player, traded down on lower than expected revenue estimates. While many are uncertain, we remain positive on ALXN's ability to continue to "beat and raise" estimates.
CSX Earnings
CSX Corporation released earnings for Q3 2012 on October 16th. They reported a net income of $455 million vs $464 million in Q3 2011, showing a decline of 1.9% year-over-year. This breaks a four-quarter streak of profit increases. A mild winter caused coal demand to be suppressed; coal composes more than a fourth of the revenue for CSX. International volume of the company grew 10%, in part due to the success of the Maersk business. The reported EPS was $.44, beating consensus marginally, which was $.43, and outperforming Q3 2011 earnings of $.43. Reported revenues were $2.89 billion, missing expectations set at $2.93 billion. Shares of CSX were down 2.2% in the afternoon sharing at $21.15.
Looking forward, the company sees itself as a neutral outlook for the fourth quarter. Estimated EPS for Q4 is $.47, and estimates are $1.85 for the fiscal year. Coal will continue to be challenged by low gas prices and high utility stockpiles, but the industrial, agricultural, construction, and domestic sectors all have favorable outlooks. There is uncertainty going forward with the company for Q4, as coal is becoming less demanded and CSX could be looking at moderate labor inflation. CSX sees itself with only moderate growth for the future.
-Peter Rodrigues, Industrial Junior Analyst
Friday, October 19, 2012
Honeywell (HON) Q3 earnings release
Honeywell came out with a good quarter in beating analysts’ estimates for a fifth quarter in a row. Having an increase in EPS of 9% to $1.20 from $1.10 it blew past estimates of 1.14 for the company. Sales for the company as a whole had a pretty shallow growth of 2% to 9.34 billion which were below estimates, but with a segment profit increase of 8% with a margin percentage increase of 110 basis points. With Net Income having a 10% increase from $862M in Q3 2011 to $920M in Q3 2012 the company has proven its investments in new products and high growth regions, such as natural gas, and a balanced mix of long- and short-term business cycles was able to offset their European weaknesses, lower demand for short-cycle products in China and the U.S., and foreign exchange headwinds in the future. Also stating a sense of confidence with maintaining a strong backlog with new platform wins across many of their different sectors.
Their guidance for sales and EPS were a little mixed, having lowered and narrowed their sales guidance outlook by 3% versus 2011 with a drop from $37.8-38.4B to $37.5-37.7B. However, they narrowed and increased their EPS guidance by 10% versus 2011 from $4.40-$4.55 to $4.45-4.50.
Following the earnings release, stock price closed today $62.49, a growth of 1.74% breaking through the $62.00 ceiling that seemed to be a resistance point for the year. Following their acquisition Thomas Russell in their UOP segment, CEO Dave Cote placed a strong emphasis on natural gas investment which seems to be the way with the future outlook of coal depleting.
Different sectors: Q4 2012 outlook (primary causes)
Aerospace- 0%-(2)% reduction because of defense program ramp downs.
Automation and Controls Solution- 1%-3% growth because of increased investments for growth and productivity yielding strong sales conversion.
Performance Materials and Technologies- 4%-6% growth because of UOP acquisition of Thomas Russell in the natural gas sector.
Transportation- (8)%-(12)% reductions because of EU light vehicle production down (–9%)
Honeywell Overall- 0%-1% ; Total $9.4-$9.6B
Baxter International (BAX) Q3 Earnings Release
Baxter International released Q3 earnings this past Thursday, 10/18.
Full year EPS guidance was narrowed as management trimmed off the top and increased the bottom of FY EPS expectations. They now expect FY$4.51-$4.54 a share, versus $4.49-$4.57. This will represent an increase of ~15% versus 2011. For Q3, BAX brought in an adjusted EPS of $1.14 per diluted share, a slight increase of 5% from Q3 2011. Management expects Q4 EPS to fall within $1.24 to $1.27. This falls within analyst expectations of $1.26 per share from $3.71 Billion in revenue.
Total revenues for the quarter were $3.5 billion, near flat with Q3 2011.
• Global Bioscience: $1.5 Billion (+5% vs 2011)
• Medical products: $2 Billion (0% vs. 2011)
Gross margin improved to 52.1%, the strongest it has been in 3 years. Expectations are that it will continue to grow for full year.
Net income rose to $583 Million from $573 Million last year.
Management guidance for full year 2012 was largely conservative at a 5% growth rate, however they predict that macro effects and exchange rate issues will erode that to roughly 2%. Moving forward, BAX wants to continue to leverage their current product portfolio in new markets while trying to expand into “unmet medical needs. “
Following Q3 earnings, BAX shares rose above our price target of 61.90 to close at $62.08. Because of the price target being met, the model will be revised for a new target price and thesis by next Monday
Full year EPS guidance was narrowed as management trimmed off the top and increased the bottom of FY EPS expectations. They now expect FY$4.51-$4.54 a share, versus $4.49-$4.57. This will represent an increase of ~15% versus 2011. For Q3, BAX brought in an adjusted EPS of $1.14 per diluted share, a slight increase of 5% from Q3 2011. Management expects Q4 EPS to fall within $1.24 to $1.27. This falls within analyst expectations of $1.26 per share from $3.71 Billion in revenue.
Total revenues for the quarter were $3.5 billion, near flat with Q3 2011.
• Global Bioscience: $1.5 Billion (+5% vs 2011)
• Medical products: $2 Billion (0% vs. 2011)
Gross margin improved to 52.1%, the strongest it has been in 3 years. Expectations are that it will continue to grow for full year.
Net income rose to $583 Million from $573 Million last year.
Management guidance for full year 2012 was largely conservative at a 5% growth rate, however they predict that macro effects and exchange rate issues will erode that to roughly 2%. Moving forward, BAX wants to continue to leverage their current product portfolio in new markets while trying to expand into “unmet medical needs. “
Following Q3 earnings, BAX shares rose above our price target of 61.90 to close at $62.08. Because of the price target being met, the model will be revised for a new target price and thesis by next Monday
Subscribe to:
Posts (Atom)